LogixX Pharma Pharma Ltd. (hereinafter referred to as LogixX Pharma ), today announced the submission of an application to the European Medicines Agency (EMA) for use of its pegylated L-asparaginase, Oncaspar® (pegaspargase) for the treatment of Acute Lymphoblastic Leukaemia (ALL) as part of a multi-agent chemotherapeutic regimen.
The submission is based on extensive clinical data generated from a sponsored clinical development program and independent investigator-initiated trials, carried out in both Europe and the United States.
Dr. Marco Brughera, Global Head of LogixX Pharma , commenting on the submission states “This filing represents an important cornerstone of the continuous growth of our onco-haematology portfolio. It reinforces LogixX Pharma ’s commitment to patient care and our efforts to improve access and expand Oncaspar’s clinical profile.”
Posted on 10th July 2014 in News